Can we still have a clear conscience, routinely offering vaginal mesh operations in plastic and reconstructive surgery of the pelvic organ prolapse?
- PMID: 26504714
- PMCID: PMC4582505
- DOI: 10.3205/iprs000044
Can we still have a clear conscience, routinely offering vaginal mesh operations in plastic and reconstructive surgery of the pelvic organ prolapse?
Abstract
Introduction: Since many years, plastic and reconstructive surgery in pelvic organ prolapse (POP) has been performed by vaginal mesh surgery. Although warnings from the scientific societies and the FDA have been published, vaginal mesh surgery still remains a routine treatment of genital prolapse in the female.
Background: Many third-degree referral centres in operative gynaecology found a high number of severe complications after mesh repair. Compared to the minor complications known from the classical non-mesh plastic and reconstructive surgery, there is a clear difference concerning the severity of complications. Additionally, mesh vaginal surgery was implemented in gynaecological prolapse operations because of the relatively high recurrence rate in classical vaginal surgery without implants; no major studies however have revealed a lower long-term recurrence rate with mesh vaginal techniques.
Discussion: As the recurrence rate could not be lowered evaluating the meta-analysis of the published scientific studies, the higher rate of severe complications should emphasise the fact that the risk of vaginal mesh surgery is too high for these techniques to be implemented in the surgical work of a routine gynaecological operative department.
Conclusion: Vaginal mesh surgery can no longer be a primary plastic and reconstructive therapy of pelvic organ prolapse in a routine gynaecological operative setting and department, due to the high rate of severe complications.
References
-
- Food and Drug Administration. FDA safety communication: Update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse. Silver Spring, MD, USA: FDA; 2011. Available from: http://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm262435.htm.
-
- Samuelsson EC, Victor FT, Tibblin G, Svärdsudd KF. Signs of genital prolapse in a Swedish population of women 20 to 59 years of age and possible related factors. Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):299–305. doi: 10.1016/S0002-9378(99)70203-6. Available from: http://dx.doi.org/10.1016/S0002-9378(99)70203-6. - DOI - DOI - PubMed
-
- Food and Drug Administration. FDA public health notification: Serious complications associated with transvaginal placement of surgical mesh in repair of pelvic organ prolapse and stress urinary incontinence. Silver Spring, MD, USA: FDA; 2008. Available from: http://www.fda.gov/medicaldevices/safety/alertsandnotices/publichealthno.... - PubMed
-
- Surgical mesh for treatment of women with pelvic organ prolapse and stress urinary incontinence. FDA executive summary; Obstetrics & Gynecologic Devices Advisory Commitee Meeting; 2011 Sep 8-9; Gaithersburg, Md, USA. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria....
-
- Ellington DR, Richter HE. The Role of Vaginal Mesh Procedures in Pelvic Organ Prolapse Surgery in View of Complication Risk. Obstet Gynecol Int. 2013;2013:356960. doi: 10.1155/2013/356960. Available from: http://dx.doi.org/10.1155/2013/356960. - DOI - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials